ALVOTECH

NASDAQ: ALVO (Alvotech)

Kemas kini terakhir: 4 hari lalu, 9:13AM

3.79

-0.09 (-2.32%)

Penutupan Terdahulu 3.88
Buka 3.86
Jumlah Dagangan 86,572
Purata Dagangan (3B) 509,384
Modal Pasaran 1,180,968,320
Harga / Pendapatan (P/E TTM) 16.48
Harga / Pendapatan (P/E Ke hadapan) 8.21
Harga / Jualan (P/S) 2.01
Julat 52 Minggu
3.65 (-3%) — 11.85 (212%)
Tarikh Pendapatan 18 Mar 2026
Margin Keuntungan 16.42%
Margin Operasi (TTM) 7.97%
EPS Cair (TTM) 0.370
Pertumbuhan Hasil Suku Tahunan (YOY) 260.00%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -65.50%
Nisbah Semasa (MRQ) 1.73
Aliran Tunai Operasi (OCF TTM) -148.89 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -216.76 M
Pulangan Atas Aset (ROA TTM) 7.02%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Bercampur Bercampur
Drug Manufacturers - Specialty & Generic (Global) Bercampur Bercampur
Stok Alvotech Menurun Menurun

AISkor Stockmoo

-1.4
Konsensus Penganalisis -2.0
Aktiviti Orang Dalam NA
Volatiliti Harga 0.5
Purata Bergerak Teknikal -1.5
Osilator Teknikal -2.5
Purata -1.38

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ALVO 1 B - 16.48 -
KNSA 4 B - 61.55 6.20
BCRX 2 B - 6.79 56.59
HROW 2 B - - 26.22
AMLX 2 B - - 4.94
ETON 462 M - - 19.37

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.

Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 63.44%
% Dimiliki oleh Institusi 6.44%

Pemilikan

Nama Tarikh Syer Dipegang
Littlejohn & Co Llc 31 Dec 2025 1,318,534
Pointstate Capital Lp 31 Dec 2025 1,049,039
Lodbrok Capital Llp 30 Sep 2025 181,587
Oaktree Fund Advisors, Llc 31 Dec 2025 146,843

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
05 Feb 2026 Pengumuman Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
05 Feb 2026 Pengumuman Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
02 Feb 2026 Pengumuman Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
02 Feb 2026 Pengumuman Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
29 Jan 2026 Pengumuman Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
29 Jan 2026 Pengumuman Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
07 Jan 2026 Pengumuman Correction: Transactions of Managers and Closely Associated Persons
06 Jan 2026 Pengumuman Transactions of Managers and Closely Associated Persons
06 Jan 2026 Pengumuman Transactions of Managers and Closely Associated Persons
06 Jan 2026 Pengumuman Alvotech announces planned CEO succession and leadership transition
06 Jan 2026 Pengumuman Alvotech announces planned CEO succession and leadership transition
31 Dec 2025 Pengumuman Alvotech Secures Term Loan Facility of USD 100 Million
31 Dec 2025 Pengumuman Alvotech Secures Term Loan Facility of USD 100 Million
29 Dec 2025 Pengumuman Changes in company's own shares
22 Dec 2025 Pengumuman Alvotech’s Financial Calendar for 2026
22 Dec 2025 Pengumuman Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
22 Dec 2025 Pengumuman Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
19 Dec 2025 Pengumuman Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
19 Dec 2025 Pengumuman Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
19 Dec 2025 Pengumuman Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
17 Dec 2025 Pengumuman Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering
16 Dec 2025 Pengumuman Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda